Investigation Report on China's Sitagliptin Market 2021-2025
|出版商||China Research and Intelligence||商品編碼||1009413|
|出版日期||內容資訊||英文 50 Pages
|中國的Sitagliptin市場分析 (2021年∼2025年) Investigation Report on China's Sitagliptin Market 2021-2025|
|出版日期: 2021年06月04日||內容資訊: 英文 50 Pages||
Sitagliptin是世界第一個口服Dipeptidyl Peptidase-4 (DPP-4) 抑制劑，2009年9月，核可進入中國市場。2020年時，Merck Sharp & Dohme Ltd是中國市場是唯一的廠商。中國國內的Sitagliptin的銷售額，從2017年的1億1698萬人民幣，達2018年2億3337萬人民幣，2020年3億8969萬人民幣。由於2022年專利屆滿，預計與進入市場其他企業競爭激烈、價格下降，市場規模進一步擴大。
Sitagliptin is the world's first listed oral dipeptidyl peptidase-4 (DPP-4) inhibitor, developed by Merck Sharp & Dohme Ltd (JANUVIA). It was approved by the U.S. FDA in October 2006 to be used as a single drug or combination with metformin and thiazolidinedione drugs to improve blood sugar control in type II diabetes. In April 2007, a combination of Sitagliptin and metformin was approved in the United States; in September 2009, the CFDA approved Sitagliptin to enter the Chinese market; in July 2012, the CFDA approved the registration of its combination in China. By 2020, Merck Sharp & Dohme Ltd is the only manufacturers in the Sitagliptin market in China.
According to CRI's market research, Sitagliptin's sales in the Chinese market have increased year by year. Sitagliptin was included in the medical insurance reimbursement catalog in 2017, so the sales value of China's Sitagliptin growth in 2018 was the most obvious, rising from CNY116.98 million in 2017 to CNY233.37 million in 2018, with an annual growth rate of 99.50%. In 2020, due to the impact of the COVID-19 epidemic, the growth rate of Sitagliptin sales fell, but the sale value of Sitagliptin reached CNY389.69 million. The CAGR of Sitagliptin's sales value in the Chinese market from 2016 to 2020 is 47.44%.
CRI expects that its sales will continue to grow from 2021 to 2025 as the effective alleviation of the COVID-19 epidemic. Chia Tai Tianqing Pharmaceutical Group Co., Ltd. successfully won the first domestic imitation of Sitagliptin after the approval in 2020, and became the fourth domestically-made DPP-4 inhibitor drug. The patent of Sitagliptin will expire in 2022. In the future, its manufacturers will gradually increase, the market will continue to expand, and prices will have a downward trend, which will lead to an increase in Sitagliptin sales and sales volume. Compared with traditional hypoglycemic drugs, sitagliptin does not increase the risk of hypoglycemia and affect weight Neutrality, good cardiovascular safety and other advantages. Based on these advantages, Sitagliptin ranks the first in the DPP-4 inhibitor market. In addition, the huge patient population. The huge patient population will enable the Sitagliptin market to continue to expand. Therefore, Sitagliptin sales will continue to grow from 2021 to 2025 as the market expands.